Site models that meet patient needs at the site level.
The overriding theme in clinical development is “get medicines to the patients faster”-and to that end, many different ideas are in the mix. One of the most significant is this evolution around the patient. To get approved medicines to patients in a clinical trial, you have to find the right patients. Many of the new solutions evolving to meet this need address patients at the site level.
At the DIA Annual Meeting in June, Christian Burns, vice president of BTC Network and ClinEdge; Sean Stanton, president and CEO at LifeCore Solutions; and Jennifer Byrne, co-founder and CEO of the newly launched Javara (see: https://bit.ly/2PzGRmE) presented “Rebuilding or Building a Research Site in the Year 2020.” During the session, they presented five site models and led the audience through an interactive discussion on how each of these are evolving to meet specific challenges. The models include virtual sites; specialty practice with research extension; dedicated research sites; large multi-physician health systems with research embedded;
and academic sites. The audience discussed the pain points around each model as follows:
Specialty practice pain points
Large multi-physician practices pain points
Dedicated research site pain points
Due to the compelling topic and interest, the session didn’t have time to delve into the virtual or academic space pain points. In the table above, SCORR Marketing, our market research survey partner, and Applied Clinical Trials wanted to focus on up-and-coming organizations that are driving innovation in each of the site models. Because of space constraints, we chose one for each, but, of course, we will continue to feature these innovators in upcoming articles in our pages and online.
- Staff report
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.